ABOUT
ABOUT US
AcadeMab is focused on developing new antibody drugs for the unmet medical need. We also develop mRNA technology as a dual-engine platform, integrating it with antibody development to drive the advancement of vaccines and related biomedical products.
ADVANTAGE
AcadeMab focuses on groundbreaking science and patient-centric innovation to provide transformative therapies that make a lasting impact on global healthcare.
PIPELINE
Our Bio
Human Antibody Mouse
AcadeMab’s antibody mouse is developed by the replacement of the original mouse antibody genes to human antibody genes. This mouse strain can generate human antibodies that have been optimized naturally through in vivo affinity maturation.
Human Single B Cell Antibody Technology
Human single B cell antibody technology is an efficient and cutting-edge approach to discovery human monoclonal antibody from vaccine recipients or convalescent patients.
Phage Display
Phage display is a molecular biology technique, that can be used to discover antibody or binding epitope by inserting the DNA sequence of scFv or peptide into the appropriate position of phage coat protein structural gene to be further expressed and displayed on the phage surface for a high throughput screening of desired targets.
Ionizable Cationic Lipids
AM-Cationic Lipid can be used to form lipid nanoparticles (LNPs) delivery vehicles, that have been used in the research of mRNA vaccine. In vitro and In vivo, these lipids exhibit the high binding affinity, acceptable encapsulation efficiency (EE) and suitable polydispersity index (PDI). Some of those lipids have been carried out Genotoxicity (Ames Test) and 14-days single dose toxicity studies.
Anti-M13 Antibody
AcadeMab develops a mouse monoclonal anti-M13 antibody which can specific recognize M13 phage coat protein P8.